Immunization with genetically modified HSCs results in protection against a growth of a model thymoma.

<p>Mice were immunized with 2×10⁴ HSC-tOVA cells following BU pre-treatment or 2×10⁴ immunodominant OVA peptide-coated DCs. (A) Percentages of OVA-specific CD8⁺ T cells in blood were monitored by OVA-specific MHC-I pentamer staining. (B) 16 weeks post immunization, mice were inoculated s.c. with 10⁶ E.G7 thymoma cells expressing OVA. Tumor growth was monitored until mice became moribund. 4 animals per group; error bars represent standard errors.